Spyre Therapeutics doses first subjects in Phase I IBD treatment trial [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
The placebo-controlled, double-blind trial is set to enrol approximately 48 healthy adult participants. It will have four single-ascending dose (SAD) and two multi-ascending dose (MAD) cohorts. Safety is the trial's primary endpoint while pharmacokinetics is the secondary endpoint. The company anticipates reporting interim safety and pharmacokinetic data from the trial by the end of this year. Based on the data from the Phase I trial, Spyre will advance the asset into the Phase II development stage next year. SPY001 is a half-life extended anti-a4ß7 monoclonal antibody. It has shown promise in preclinical studies, demonstrating equivalent potency to vedolizumab in blocking MadCAM-1 adhesion. In addition, it exhibited a significantly longer half-life, suggesting the potential for less frequent dosing, possibly once every two or three months. Spyre Therapeutics CEO Cameron Turtle said: “SPY001 is the first of our programmes across three of the most impactful mechanisms in
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-a4ß7 Antibody, for the Treatment of Inflammatory Bowel Disease [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-a4ß7 Antibody, for the Treatment of Inflammatory Bowel DiseasePR Newswire
- Spyre Therapeutics Announces Grants of Inducement AwardsPR Newswire
- Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics to Participate in the Jefferies Global Healthcare ConferencePR Newswire
SYRE
Earnings
- 5/9/24 - Miss
SYRE
Sec Filings
- 6/10/24 - Form SC
- 5/30/24 - Form 8-K
- 5/16/24 - Form 4
- SYRE's page on the SEC website